WO2024194662 - PROCESS FOR THE PREPARATION OF UPADACITINIB

National phase entry is expected:
Publication Number WO/2024/194662
Publication Date 26.09.2024
International Application No. PCT/HU2024/050019
International Filing Date 22.03.2024
Title **
[English] PROCESS FOR THE PREPARATION OF UPADACITINIB
[French] PROCÉDÉ DE PRÉPARATION D'UPADACITINIB
Applicants **
EGIS GYÓGYSZERGYÁR ZRT. Keresztúri út 30-38. 1106 Budapest, HU
Inventors
MÁNDI, Géza Rózsa u. 46. 2A 1064 Budapest, HU
NAGY, Tamás Hunyad lejtő 28/2 1121 Budapest, HU
PORCS-MAKKAY, Márta Hunyadi János utca 22B 1a 1188 Budapest, HU
ABONYI, Attila László Aranylúd utca 4 1173 Budapest, HU
KURUNCZI, Erika Drégelyvár utca 21 4/23 1158 Budapest, HU
Priority Data
P2300098   23.03.2023   HU
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing1153
EPO Filing, Examination6702
Japan Filing535
South Korea Filing576
USA Filing, Examination3425
MasterCard Visa

Total: 12391

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] The object of the invention is the preparation of upadacitinib drug substance of the formula (I) by a new process, which is novel, environmentally friendly, has an advantageous pollution profile, and also can be realized on an industrial scale, using novel intermediates not yet known from the literature.[French] L'objet de l'invention est la préparation d'une substance médicamenteuse, l'upadacitinib, de formule (I) au moyen d'un nouveau procédé, qui est nouveau, respectueux de l'environnement, a un profil de pollution avantageux, et peut également être mis en oeuvre à l'échelle industrielle, à l'aide de nouveaux intermédiaires non encore connus de la littérature.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙